Effects of pretreatment with statins on infarct size in patients with acute myocardial infarction Who receive fibrinolytic therapy

Circulation Journal

Volumn 73, Issue 2, 2009, Pages 330-335

  Kiyokuni, Masayoshi ^a   Kosuge, Masami ^a   Ebina, Toshiaki ^a   Hibi, Kiyoshi ^a   Tsukahara, Kengo ^a   Okuda, Jun ^a   Iwahashi, Noriaki ^a   Maejima, Nobuhiko ^a   Kusama, Ikuyoshi ^a   Komura, Naohiro ^a   Nakayama, Naoki ^a   Umemura, Satoshi ^a   Kimura, Kazuo ^a  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Acute myocardial infarction; Electrocardiogram; Fibrinolysis; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CREATINE KINASE; FLUINDOSTATIN; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MONTEPLASE; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CORONARY REPERFUSION; ELECTROCARDIOGRAM; FEMALE; FIBRINOLYSIS; HEART INFARCTION SIZE; HUMAN; MAJOR CLINICAL STUDY; MALE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASPIRIN; CREATINE KINASE; ELECTROCARDIOGRAPHY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; REPERFUSION INJURY; RETROSPECTIVE STUDIES; THROMBOLYTIC THERAPY;

EID: 59449095738     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-08-0576     Document Type: Article

References (26)

1. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-213.
2. Dulak J, Loboda A, Jazwa A, Zagorska A, Dörler J, Alber H, et al. Atorvastatin affects several angiogenic mediators in human endothelial cells. Endothelium 2005; 12: 233-241.
3. Stefanadi E, Tousoulis D, Antoniades C, Katsi V, Bosinakou E, Vavuranakis E, et al. Early initiation of low-dose atorvastatin treatment after an acute ST-elevated myocardial infarction, decreases inflammatory process and prevents endothelial injury and activation. Int J Cardiol 2008 [Epub ahead of print].
4. Krysiak R, Okopien B, Herman Z. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes. Drugs 2003; 63: 1821-1854.
5. Zhang L, Zhang ZG, Ding GL, Jiang Q, Liu X, Meng H, et al. Multi-targeted effects of statin-enhanced thrombolytic therapy for stroke with recombinant human tissue-type plasminogen activator in the rat. Circulation 2005; 112: 3486-3494.
6. TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial: Phase I findings. N Engl J Med 1985; 312: 932-936.
7. Noda T, Minatoguchi S, Fujii K, Hori M, Ito T, Kanmatsuse K, et al. Evidence for the delayed effect in human ischemic preconditioning: Prospective multicenter study for preconditioning in acute myocar-dial infarction. J Am Coll Cardiol 1999; 34: 1966-1974.
8. Rentrop KP, Cohen M, Blanke H, Phillips RA. Changes in collateral channel filling immediately after controlled coronary artery occlusion by an angioplasty balloon in human subjects. J Am Coll Cardiol 1985; 5: 587-592.
9. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
10. Ideker RE, Wagner GS, Ruth WK, Alonso DR, Bishop SP, Bloor CM, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. II: Correlation with quantitative anatomic findings for anterior infarcts. Am J Cardiol 1982; 49: 1604-1614.
11. Juergens CP, Fernandes C, Hasche ET, Meikle S, Bautovich G, Currie CA, et al. Electrocardiographic measurement of infarct size after thrombolytic therapy. J Am Coll Cardiol 1996; 27: 517-524.
12. Vollmer RT, Christenson RH, Reimer K, Ohman EM. Temporal creatine kinase curves in acute myocardial infarction: Implications of a good empiric fit with the log-normal function. Am J Clin Pathol 1993; 100: 293-298.
13. Ishii H, Ichimiya S, Kanashiro M, Aoyama T, Ogawa Y, Murakami R, et al. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: A retrospective study in patients undergoing primary percutaneous coronary intervention. Clin Ther 2006; 28: 1812-1819.
14. Zhang RL, Zhang ZG, Chopp M, Zivin JA. Thrombolysis with tissue plasminogen activator alters adhesion molecule expression in the ischemic rat brain. Stroke 1999; 30: 624-629.
15. Koh KK, Son JW, Ahn JY, Jin DK, Kim HS, Choi YM, et al. Comparative effects of diet and statin on NO bioactivity and matrix metal-loproteinases in hypercholesterolemic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2002; 22: e19-e23.
16. Kim EY, Heo JH, Lee SK, Kim DJ, Suh SH, Kim J, et al. Prediction of thrombolytic efficacy in acute ischemic stroke using thin-section noncontrast CT. Neurology 2006; 67: 1846-1848.
17. Zhang ZG, Zhang L, Tsang W, Goussev A, Powers C, Ho KL, et al. Dynamic platelet accumulation at the site of the occluded middle cerebral artery and in downstream microvessels is associated with loss of microvascular integrity after embolic middle cerebral artery occlusion. Brain Res 2001; 912: 181-194.
18. Wagner GS, Freye CJ, Palmeri ST, Roark SF, Stack NC, Ideker RE, et al. Evaluation of a QRS scoring system for estimating myocardial infarct size. I: Specificity and observer agreement. Circulation 1982; 65: 342-347.
19. Willems JL, Willems RJ, Willems GM, Arnold AE, Van de Werf F, Verstraete M. Significance of initial ST segment elevation and depression for the management of thrombolytic therapy in acute myocardial infarction for the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Circulation 1990; 82: 1147-1158.
20. Barbagelata A, Califf RM, Sgarbossa EB, Knight D, Mark DB, Granger CB, et al; GUSTO-1 Investigators. Prognostic value of pre-discharge electrocardiographic measurement of infarct size after thrombolysis: Insights from GUSTO I Economics and Quality of Life substudy. Am Heart J 2004; 148: 795-802.
21. Kim YS, Ahn Y, Hong MH, Kim KH, Park HW, Hong YJ, et al. Rosuvastatin suppresses the inflammatory responses through inhibition of c-Jun N-terminal kinase and nuclear factor-[kappa]B in endothelial cells. J Cardiovasc Pharmacol 2007; 49: 376-383.
22. Matsuki A, Igawa A, Nozawa T, Nakadate T, Igarashi N, Nonomura M, et al. Early administration of fluvastatin, but not at the onset of ischemia or reperfusion, attenuates myocardial ischemia-reperfusion injury through the nitric oxide pathway rather than its antioxidant property. Circ J 2006; 70: 1643-1649.
23. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001; 103: 926-933.
24. Bao N, Minatoguchi S, Kobayashi H, Yasuda S, Kawamura I, Iwasa M, et al. Pravastatin reduces myocardial infarct size via increasing protein kinase C-dependent nitric oxide, decreasing oxyradicals and opening the mitochondrial adenosine triphosphate-sensitive potassium channels in rabbits. Circ J 2007; 71: 1622-1628.
25. Lee TM, Lin MS, Chang NC. Effect of pravastatin on sympathetic reinnervation in post-infarcted rats running title: Pravastatin and re-innervation. Am J Physiol Heart Circ Physiol 2007; 10: 3617-3626.
26. Hoffmann R, Haager P, Suliman H, Christott P, Radke P, Blindt R, et al. Effect of statin therapy before Q-wave myocardial infarction on myocardial perfusion. Am J Cardiol 2008; 101: 139-143.